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Screening for Unhealthy Drug Use
Updated Evidence Report and Systematic Review
for the US Preventive Services Task Force
Carrie D. Patnode, PhD, MPH; Leslie A. Perdue, MPH; Megan Rushkin, MPH; Tracy Dana, MLS; Ian Blazina, MPH;
Christina Bougatsos, MPH; Sara Grusing, BA; Elizabeth A. O’Connor, PhD; Rongwei Fu, PhD; Roger Chou, MD
Editorial page 2263
IMPORTANCE Illicit drug use is among the most common causes of preventable morbidity
and mortality in the US.

Related article page 2301 and
JAMA Patient Page page 2350

OBJECTIVE To systematically review the literature on screening and interventions for drug use

Supplemental content

to inform the US Preventive Services Task Force.
DATA SOURCES MEDLINE, PubMed, PsycINFO, Embase, and Cochrane Central Register

of Controlled Trials through September 18, 2018; literature surveillance through
September 21, 2019.

Related articles at
jamapsychiatry.com
jamainternalmedicine.com

STUDY SELECTION Test accuracy studies to detect drug misuse and randomized clinical trials
of screening and interventions to reduce drug use.
DATA EXTRACTION AND SYNTHESIS Critical appraisal and data abstraction by 2 reviewers
and random-effects meta-analyses.
MAIN OUTCOMES AND MEASURES Sensitivity, specificity, drug use and other health, social,

and legal outcomes.
RESULTS Ninety-nine studies (N = 84 206) were included. Twenty-eight studies (n = 65 720)
addressed drug screening accuracy. Among adults, sensitivity and specificity of screening
tools for detecting unhealthy drug use ranged from 0.71 to 0.94 and 0.87 to 0.97,
respectively. Interventions to reduce drug use were evaluated in 52 trials (n = 15 659) of
psychosocial interventions, 7 trials (n = 1109) of opioid agonist therapy, and 13 trials (n = 1718)
of naltrexone. Psychosocial interventions were associated with increased likelihood of drug
use abstinence (15 trials, n = 3636; relative risk [RR], 1.60 [95% CI, 1.24 to 2.13]; absolute risk
difference [ARD], 9% [95% CI, 5% to 15%]) and reduced number of drug use days (19 trials,
n = 5085; mean difference, –0.49 day in the last 7 days [95% CI, –0.85 to –0.13]) vs no
psychosocial intervention at 3- to 4-month follow-up. In treatment-seeking populations,
opioid agonist therapy and naltrexone were associated with decreased risk of drug use
relapse (4 trials, n = 567; RR, 0.75 [95% CI, 0.59 to 0.82]; ARD, –35% [95% CI, –67% to –3%]
and 12 trials, n = 1599; RR, 0.73 [95% CI, 0.62 to 0.85]; ARD, –18% [95% CI, –26% to –10%],
respectively) vs placebo or no medication. While evidence on harms was limited, it indicated
no increased risk of serious adverse events.
CONCLUSIONS AND RELEVANCE Several screening instruments with acceptable sensitivity and
specificity are available to screen for drug use, although there is no direct evidence on the
benefits or harms of screening. Pharmacotherapy and psychosocial interventions are
effective at improving drug use outcomes, but evidence of effectiveness remains primarily
derived from trials conducted in treatment-seeking populations.
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I

llicit drug use is among the most common causes of preventable morbidity and mortality in the US and a leading cause of
years lived in disability.1,2 In 2018, an estimated 11.7% of US residents 12 years or older were current illicit drug users (hereafter “drug
use” and generally defined as use of illegal drugs and the nonmedical use of prescription medications).3 This estimate largely represented use of marijuana (10.1%; estimated 27.7 million current users)
and nonmedical prescription psychotherapeutic drugs (2.0%; estimated 5.4 million current users), particularly pain relievers (1.0%;
estimated 2.9 million current users).3 It was estimated that nearly
84% of those who needed treatment for a drug use disorder did not
receive specialty treatment during the past year.3 As such, screening for drug use is important, as it may allow clinicians to counsel patients and, when indicated, refer them to treatment.

In 2008, the US Preventive Services Task Force (USPSTF) concluded that there was insufficient evidence to recommend for or
against screening adolescents and adults, including pregnant women,
for illicit drug use (I statement).4 The objective of this review was
to inform an updated recommendation by the USPSTF.

Methods
Scope of Review
This is an update of a systematic review5 and supplemental report6
that served as the basis for the 2008 recommendation. An analytic
framework was developed with 7 key questions (KQs) (Figure 1) on
the benefits (KQ1) and harms (KQ3) of screening for drug use,

Figure 1. Analytic Framework: Screening for Illicit Drug Use, Including Nonmedical Use of Prescription Drugs
1
4, 6
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pregnant women
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Frequency and/or quantity of drug use
Other risky behaviors
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Mortality
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Key questions
1

a. Does primary care screeninga for drug useb in adolescents and adults, including pregnant women, reduce drug use
or improve other risky behaviors?
b. Does primary care screeninga for drug useb in adolescents and adults, including pregnant women, reduce morbidity
or improve other health, social, or legal outcomes?

2

What is the accuracy of drug use screening instruments?

3

What are the harms of primary care screeninga for drug useb in adolescents and adults, including pregnant women?

4

a. Do interventions to reduce drug useb reduce drug use or improve other risky behaviors?
b. Do interventions to reduce drug useb reduce morbidity or mortality or improve other health, social, or legal outcomes?

5

What are the harms of interventions to reduce drug useb?

6

Does naloxone reduce morbidity or mortality, or improve other health outcomes in persons with opioid use
disorder or misuse?

7

What are the harms of naloxone in persons with opioid use disorder or misuse?

Evidence reviews for the US Preventive Services Task Force (USPSTF) use an
analytic framework to visually display the key questions that the review will
address to allow the USPSTF to evaluate the effectiveness and safety of
a preventive service. The questions are depicted by linkages that relate
interventions and outcomes. A dashed line indicates a health outcome that
immediately follows an intermediate outcome.

a

Screening refers to screening methods that pose questions about drug use or
drug-related risks, not laboratory testing of biologic samples for the presence
of drugs.

b

Includes illicit drug use and nonmedical pharmaceutical drug use.
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screening test accuracy (KQ2), benefits (KQ4) and harms (KQ5) of interventions to reduce drug use, and the benefits (KQ6) and harms
(KQ7) of preemptively prescribed naloxone in persons with opioid use
disorder or misuse. This article summarizes data from 2 reports: one
focused on screening for drug use and interventions in screendetected populations7 and the other addressing interventions among
patients with known drug use or seeking treatment
(“treatment-seeking”).8 Both full reports are available at https://
uspreventiveservicestaskforce.org/uspstf/recommendation/druguse-illicit-screening. All results presented in the full reports are also
presented in this article; more detailed methods and all forest plots
are included in the full reports.

Data Sources and Searches
MEDLINE, PubMed, PsycINFO, the Cochrane Central Register
of Controlled Trials (CENTRAL), Cochrane Database of Systematic
Reviews, and EMBASE were searched for relevant Englishlanguage literature (eMethods in the Supplement). Searches
encompassed literature published between January 1, 1998,
and June 7, 2018, for KQs 1-3 and from database inception to
September 18, 2018, for KQs 4-7. The reference lists of relevant
studies and expert suggestions supplemented the electronic
searches. ClinicalTrials.gov (https://ClinicalTrials.gov/) and the WHO
International Clinical Trials Registry Platform (https://www.who.int/
ictrp) were searched for ongoing trials. Active surveillance was
conducted through September 21, 2019, through article alerts,
targeted journal searches, and public comment to identify major
studies that might affect the conclusions or understanding of the
evidence. Four new test accuracy studies were identified to detect
drug use disorder among adults and drug use among pregnant
women.9-12 Additionally, 1 new trial13 of a psychosocial intervention
among adolescents identified through screening was identified. These
studies would not substantively change the findings or conclusions
of this review and are not included in the results of this study.

Study Selection
At least 2 reviewers independently reviewed all identified titles and
abstracts and relevant full-text articles to ensure consistency with
predetermined inclusion and exclusion criteria (eTable 1 in the
Supplement). For all KQs, studies among adolescents (defined as persons aged 12 to 17 years) and adults were included, including pregnant adolescents and adults. Studies screening for any illicit psychoactive or nonmedical pharmaceutical drug use were included, as
were interventions targeting use of opioids, stimulants (eg, cocaine, methamphetamines), cannabis, or mixed drug use. For KQ1
and KQ3, randomized clinical trials or nonrandomized controlled intervention studies that compared individuals who received screening with those who received no screening or usual care were included. For KQ2, studies reporting sensitivity and specificity (or data
to calculate) of a screening instrument to detect unhealthy drug use
(including any drug use and drug use disorders) compared with a
structured or semistructured clinical interview or biological samples
were included.
Case-controlstudieswereexcluded.Eligiblescreeninginstruments
included brief standardized instruments or a set of questions that
screened directly for drug use or drug use risk or those that indirectly
screened for drug use with questions regarding alcohol use or other
risky behaviors. Studies evaluating the accuracy of biological drug
2312
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screening tests (eg, urine samples) were not included. Given the variabilityintargetconditionspresentedacrossthestudies,conditionswere
collapsed into 3 groups: any use, unhealthy use (variably defined in the
studies), or use disorder (Diagnostic and Statistical Manual of Mental
Disorders (Fourth Edition) [DSM-IV] abuse or dependence, Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) [DSM-5]
use disorder). The target condition of “unhealthy use” included conditions such as the full spectrum of unhealthy use (eg, problem use or
a use disorder), meeting any DSM criterion for a use disorder, heavy use
(eg,usingasubstancetwiceormoreperday)ornegativeconsequences
or problems related to drug use.
For evaluation of drug use interventions (KQs 4-7), eligible trials
could enroll screen-detected patients or those seeking substanceuse treatment or with signs and symptoms of drug use, regardless
of drug use severity. Eligible psychosocial interventions used 1 or
more of the following techniques: cognitive behavioral therapy (CBT),
motivational interventions, contingency management, 12-step facilitation therapy, family interventions, and adaptations of these
methods.14 Interventions could be delivered in-person or using other
modalities (eg, telephone, internet, or computer) and were categorized as brief (1 or 2 sessions, each less than 1 hour in duration) or
intensive (not brief). Comparators included no intervention, usual
care, or a brief intervention.
For pharmacotherapy, inclusion was restricted to US Food and
Drug Administration (FDA)–approved medications for drug use disorders. As of September 2018, this included medications for treatment of opioid use disorder: buprenorphine (sublingual, buccal, or
extended-release injection or implant), buprenorphine/naloxone
(sublingual or buccal), methadone, and naltrexone (oral or extendedrelease injection). While implantable naltrexone is not FDAapproved, it was also included because evidence on injectable naltrexone was limited. Comparators included no intervention, usual
care, or placebo. Trials of methadone or buprenorphine detoxification (withdrawal management) were excluded. For KQ6 and KQ7,
studies of preemptive naloxone prescribed in clinical settings as a
rescue medication for acute overdose events were included.
Outcomes were drug use (ie, abstinence, frequency and/or
quantity of drug use, severity of drug use disorder), clinical outcomes (ie, all-cause mortality, drug-related mortality and morbidity, obstetrical/perinatal/neonatal outcomes, quality of life), other
drug-related consequences (ie, legal problems, social and family relations, employment, school/educational outcomes), and harms,
including serious adverse events such as death and adverse events
resulting in hospitalizations or study withdrawal reported at least 3
months after baseline measurement. Retention in substance use
treatment was also an outcome for pharmacological therapy.

Data Extraction and Quality Assessment
Two reviewers independently assessed the methodological quality
of eligible studies. Disagreements were resolved by consensus
and, if needed, consultation with a third reviewer. Each study was
assigned a quality rating of “good,” “fair,” or “poor” according to the
USPSTF study design–specific criteria (eTable 2 in the Supplement).15
In accordance with the USPSTF Procedure Manual, studies rated as
poor quality because of serious methodological shortcomings were
excluded.15 One reviewer abstracted descriptive and outcome data
from fair- and good-quality studies into standardized evidence tables
and a second checked for accuracy and completeness.
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Data Synthesis and Analysis
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No eligible studies were identified.

Summary tables of study, population, screening, and intervention
characteristics, as well as outcomes for each KQ, were created according to the type of screening instrument or intervention. The data
for screening accuracy did not allow for quantitative pooling given
the heterogeneity in instruments, reference conditions, and cutoffs included, so synthesis was qualitative. Screening instruments
were categorized as (1) frequency-based (addressing any use, frequency of use, or both), (2) risk assessment (addressing the consequences of drug use, typically indicators of a use disorder and often with drug use frequency), or (3) indirect (did not screen for drug
use directly but assessed correlates of drug use, such as alcohol or
tobacco use, partner substance use, and other social factors).
For intervention effectiveness, data were analyzed separately for
psychosocialinterventions,opioidagonists(methadoneandbuprenorphine), and naltrexone. Meta-analyses were conducted using a random-effects profile likelihood model on abstinence (or relapse), drug
use days, retention in treatment, drug use severity, and harms. Results were analyzed separately for outcomes assessed at 3 or 4 months
and at 6 to 12 months. Drug use days were standardized to the number of days of drug use during the past 7 days. Drug use severity was
analyzed as a standardized mean difference, given heterogeneity in
measurement scales. Stratified analyses were conducted according to
whether the population was screen-detected or treatment-seeking,
the main type of drug measured (cannabis, stimulant, opioid, or mixed
drugs), age group (adolescent [12-17 years], young adult [18-25 years],
or adult [>25 years]), study quality, and pregnancy or postpartum status. For pharmacotherapies, stratified analyses were also conducted
by route of administration, naltrexone dose, timing of outcome assessment, and intensity of the interventions. For psychosocial interventions, analyses were also conducted according to intervention intensity (brief vs intensive) and mode of delivery (face-to-face or other).
Heterogeneity between studies was evaluated by the χ2 test
and I2 statistics. Analyses were conducted using Stata version 13.1
(StataCorp). All significance testing was 2-sided, and P ⱕ .05 was
considered statistically significant.
TheaggregatestrengthofevidencewasassessedforeachKQusing
the approach described in the Agency for Healthcare Research and
Quality methods guidance, based on the number, quality, and size of
studies and the consistency and precision of results between studies.16

Results
A total of 28 012 titles and abstracts and 1398 articles were reviewed for eligibility; of these, 99 studies (N = 84 206) reported in
124 publications were included (Figure 2). Twenty-eight studies
(n = 65 720) addressed the accuracy of drug use screening instruments, and 71 trials evaluated psychosocial interventions (52 trials,
n = 15 659), opioid agonist therapy (7 trials, n = 1109), or naltrexone (13 trials, n = 1718) to reduce drug use.

Benefits of Screening
Key Question 1. Does primary care screening for drug use in adolescents and adults, including pregnant women, reduce drug use or improve other risky behaviors? Does primary care screening for drug use
in adolescents and adults, including pregnant women, reduce morbidity or mortality or improve other health, social, or legal outcomes?

Screening Accuracy
Key Question 2. What is the accuracy of drug use screening
instruments?
Twenty-eight studies17-44 (reported in 37 publications17-52) with
65 720 participants addressed the accuracy of drug use screening
instruments. Considerable heterogeneity among studies was present in the populations (eTable 3 in the Supplement), screening instruments (eTable 4 in the Supplement), substances addressed, reference standards, and target conditions. Specific screening
instruments were generally not examined in more than 1 or 2 studies. Eleven studies recruited adolescents, 12 studies recruited adults,
and 5 studies recruited pregnant or postpartum people (eTable 3 in
the Supplement). Twenty-one of 28 studies were conducted in the
US, and 17 of 28 recruited patients from primary care. The number
screened ranged from 100 to 42 923, with the majority (20/28 studies) screening fewer than 1000 participants.
Most studies used a structured diagnostic interview as the substance use reference standard, sometimes in combination with
other screening instruments (eg, ASSIST [Alcohol, Smoking and
Substance Involvement Screening Test]), a timeline follow-back
method,53 or biologic confirmation. Seventeen of 28 studies were
fair quality, with methodological shortcomings including not
reporting enough information regarding the order and timing of
the reference standard and screening instrument; not clearly
reporting whether the researchers had knowledge of the screening
instrument results during the administration and interpretation of
the reference standard; not presenting a range of screening instrument cutoff values and selecting only the optimal cutoff; and
unclear reporting of whether participant recruitment was random
or consecutive.
Thirty screening instruments were evaluated. The screening instruments varied in the number of questions (range, 1-31), administration time, administration method (eg, in-person, telephone, electronic), and the substances addressed. Most of the screening
instruments addressed the use of any drug (with or without addressing alcohol and tobacco use). Among these, the majority included an assessment of nonmedical use of prescription drugs, either
through a specific question or by including it in the definition of drug
use in the prescreening instructions.
Among adults, frequency- and risk-based screening tools
showed sensitivity for detecting unhealthy use of any drug ranging
from 0.71 to 0.94 (95% CI range, 0.62 to 0.97) and specificity ranging from 0.87 to 0.97 (95% CI range, 0.83 to 0.98) (3 studies,
n = 1512) (Table 1; eTable 5 in the Supplement). For identifying drug
use disorders among adults, sensitivity for frequency-based and
risk assessment tools ranged from 0.85 to 1.00 (95% CI range, 0.67
to 1.00) and specificity ranged from 0.67 to 0.93 (95% CI, 0.58 to
0.95) (4 studies, n = 1651). In studies that examined unhealthy use
of specific drugs, the ranges of sensitivity were lower and less precise for detecting unhealthy use or use disorders for prescription
opioids and prescription sedatives (sensitivity ranged from 0.38 to
0.89 [95% CI range, 0.29 to 0.94]), compared with other classes
of drugs. Confidence intervals, however, generally overlapped.
Specificity for detecting unhealthy use or use disorders due to prescription misuse was comparable and ranged from 0.79 to 0.99
[95% CI range, 0.71 to 0.99]).
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Counts of full-text articles reviewed are not mutually exclusive; some articles were reviewed for both reports.

Reasons for exclusion: Aim: Not applicable/relevant to key question. Setting: Not conducted in a very high
Human Development Index country or screening and/or intervention was not conducted in, recruited from,
or feasible for primary care. Screener: Assessment for drug use does not include a brief standardized instrument
or set of questions conducted in person or via telephone, mail, or electronically. Study design: Not a randomized

18 Articles (18 studies)
included for KQ5

0 Articles included for KQ6

1038 Articles excluded for KQs 4-7c
20 Setting
71 Study design
43 Follow-up <3 mo
43 Outcomes
138 Population
321 Comparator
212 Publication type
7 Quality
183 Intervention

1125 Articles reviewed for KQs 4-7

1125 Full-text articles assessed for eligibilityb

0 Articles included for KQ7

clinical trial or case-crossover trial (KQs 1, 3, 4, 5); not a large cohort or case-control study (KQ2). Follow-up
<3 mo: Less than 3 months’ follow-up after baseline assessment. Outcomes: No measure of drug use reported
(KQs 1, 3, 4, 5); no measure related to sensitivity and specificity reported for screening accuracy (KQ2).
Population: Children younger than 12 years or populations otherwise out of scope (eg, psychotic disorder,
receiving chronic opioid therapy, court-mandated drug treatment, or incarcerated). Comparator: Not an
included comparator (eg, screening results given to control clinicians [KQs 1 and 3], no reference standard [KQ2],
active intervention [KQs 4 and 5]). Publication type: Conference abstract, non–English-language publication,
main results published prior to review start date (1992). Quality: Study was poor quality.

87 Articles (71 studies)
included for KQ4

c

0 Articles included for KQ3

b

37 Articles (28 studies)
included for KQ2

0 Articles included for KQ1

4 Articles excluded
for KQ3c
1 Screener
2 Study design
1 Quality

Number of citations screened after duplicates removed also reflects studies reviewed for key questions (KQs) 4
and 5 (efficacy and harms of psychosocial interventions in screen-detected populations) in the Screening for
Drug Use Report.

78 Articles excluded for KQ2c
2 Aim
13 Setting
7 Screener
7 Study design
10 Outcomes
17 Population
12 Comparator
10 Quality

4 Articles excluded
for KQ1c
1 Screener
2 Study design
1 Quality

4 Articles reviewed for KQ3

a

115 Articles reviewed for KQ2

4 Articles reviewed for KQ1

273 Full-text articles assessed for eligibilityb

8966 Citations excluded at abstract
and title stage

10 091 Citations screened after duplicates removeda

17 921 Citations screened after duplicates removeda

17 648 Citations excluded at abstract
and title stage

Interventions
14 906 Citations identified
14 771 Literature database searches
17 Previous systematic reviews
118 Other sources

Screening

34 143 Citations identified
34 037 Literature database searches
74 Previous systematic reviews
32 Other sources

Figure 2. Literature Search Flow Diagram: Screening for Illicit Drug Use, Including Nonmedical Use of Prescription Drugs
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Table 2. Summary of Pooled Findings: Psychosocial Interventions (Key Question 4)
Outcome,
Timing

Study characteristics

Group analyzed

No. of trials

Effect size (95% CI)

I2, %

P value

Abstinence
3-4 mo

All trials

All participants

15

RR, 1.60 (1.24 to 2.13)

61

Type of drug use

Cannabis

7

RR, 2.08 (1.51 to 3.07)

28

Mixed drugs

7

RR, 1.24 (0.92 to 1.80)

60

Prescription drugs

1

RR, 2.08 (0.81 to 5.38)

Screen-detected population

8

RR, 1.28 (0.97 to 1.84)

57

Treatment-seeking population

7

RR, 2.08 (1.51 to 3.07)

28

Population

Type of intervention

Age group
Pregnancy statusa

Mode of delivery

Study quality

6-12 mo

Brief interventions

10

RR, 1.46 (1.11 to 2.09)

56

Other (more intensive) interventions

6

RR, 2.01 (1.17 to 3.58)

70

Adolescent/young adult

2

RR, 1.54 (0.78 to 5.22)

61

Adult

13

RR, 1.58 (1.20 to 2.16)

64

Pregnant or postpartum

5

RR, 1.24 (0.99 to 1.89)

41

Not pregnant or postpartum

8

RR, 1.77 (1.17 to 2.80)

71

Face-to-face

7

RR, 1.77 (1.13 to 3.02)

76

Other (web, computer, telephone)

8

RR, 1.43 (1.10 to 2.04)

35

Good

1

RR, 4.34 (1.75 to 10.72)

Fair

14

RR, 1.50 (1.18 to 1.98)

56

All trials

All participants

14

RR, 1.25 (1.11 to 1.52)

38

Type of drug use

Cannabis

4

RR, 1.58 (1.17 to 2.73)

36

Population

Type of intervention

Age group
Postpartum statusa

Mode of delivery

Study quality

Stimulants

4

RR, 1.45 (0.86 to 2.56)

65

Mixed drugs

5

RR, 1.12 (0.92 to 1.36)

0

Prescription drugs

1

RR, 1.25 (0.65 to 2.40)

Screen-detected population

7

RR, 1.17 (0.99 to 1.41)

2

Treatment-seeking population

7

RR, 1.51 (1.14 to 2.37)

57

Brief interventions

11

RR, 1.22 (1.08 to 1.42)

14

Other (more intensive) interventions

3

RR, 1.99 (0.55 to 7.80)

71

Adolescent/young adult

5

RR, 1.25 (1.04 to 1.64)

14

Adult

9

RR, 1.30 (1.05 to 1.80)

51

Postpartum

2

RR, 1.07 (0.76 to 1.71)

0

Not postpartum

7

RR, 1.41 (1.04 to 2.16)

57

Face-to-face

11

RR, 1.31 (1.13 to 1.69)

43

Other (web, computer, telephone)

3

RR, 1.04 (0.73 to 1.45)

0

Good

2

RR, 1.11 (0.58 to 1.51)

58

Fair

12

RR, 1.35 (1.15 to 1.73)

35

.10

.05

.34

.77

.61

.10

.43

.26

.22

.52

.23

.21

Drug use daysb
3-4 mo

All trials

All participants

19

MD, −0.49 (−0.85 to −0.13)

89

Type of drug use

Cannabis

14

MD, −0.68 (−1.14 to −0.23)

89

Any drug use

5

MD, −0.05 (−0.39 to 0.31)

58

Screen-detected population

9

MD, −0.10 (−0.31 to 0.12)

46

Treatment-seeking population

10

MD, −0.91 (−1.52 to −0.31)

86

Population

Type of intervention

Age group

Mode of delivery

Study quality

Brief interventions

9

MD, −0.13 (−0.36 to 0.12)

42

Other (more intensive) interventions

10

MD, −0.88 (−1.50 to −0.28)

91

Adolescent

1

MD, −1.47 (−2.99 to 0.06)

Young adult or adolescent/young
adult

8

MD, −0.15 (−0.37 to 0.03)

0

Adult

10

MD, −0.63 (−1.22 to −0.03)

93

Face-to-face

14

MD, −0.54 (−1.01 to −0.08)

90

Other (web, computer, telephone)

5

MD, −0.27 (−0.82 to 0.13)

49

Good

5

MD, −0.42 (−1.30 to 0.48)

93

Fair

14

MD, −0.51 (−0.93 to −0.11)

86

.11

.02

.03

.38

.66

.82
(continued)
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Table 2. Summary of Pooled Findings: Psychosocial Interventions (Key Question 4) (continued)
Outcome,
Timing
6-12 mo

Study characteristics

Group analyzed

No. of trials

Effect size (95% CI)

I2, %

All trials

All participants

15

MD, −0.08 (−0.30 to 0.11)

45
41

Type of drug use

Population

Type of intervention

Age group

Mode of delivery

Study quality

Cannabis

7

MD, −0.21 (−0.65 to 0.16)

Stimulants

1

MD, −0.47 (−1.17 to 0.24)

Any drug use

7

MD, 0.04 (−0.22 to 0.28)

43

Screen-detected population

10

MD, 0.00 (−0.24 to 0.22)

42

Treatment-seeking population

5

MD, −0.29 (−0.69 to 0.09)

12

P value

.42

Brief interventions

11

MD, −0.06 (−0.24 to 0.11)

0

Other (more intensive) interventions

4

MD, −0.16 (−0.88 to 0.46)

79

Young adult or adolescent/
young adult

7

MD, −0.09 (−0.34 to 0.12)

0

Adult

8

MD, −0.07 (−0.40 to 0.22)

66

.22

.90

.80

Face-to-face

13

MD, −0.10 (−0.36 to 0.12)

53

Other (web, computer, telephone)

2

MD, −0.05 (−0.42 to 0.38)

0

Good

6

MD, −0.12 (−0.46 to 0.16)

36

Fair

9

MD, −0.04 (−0.38 to 0.23)

45

65

.80

.70

Drug use
severity
6-12 mo

All trials

All participants

13

SMD, −0.10 (−0.24 to 0.02)

Type of drug use

Amphetamine use

1

SMD, 0.10 (−0.35 to 0.54)

Cannabis use

8

SMD, −0.16 (−0.37 to 0.03)

72

Mixed substance use

4

SMD, −0.001 (−0.18 to 0.12)

42

Screen-detected population

9

SMD, −0.03 (−0.15 to 0.06)

40

Treatment-seeking population

4

SMD, −0.23 (−0.62 to 0.17)

82

Population

Type of intervention

Age group

Mode of delivery

Study quality

Brief interventions

10

SMD, −0.02 (−0.13 to 0.06)

35

Other (more intensive) interventions

3

SMD, −0.36 (−0.80 to 0.14)

71

Adolescent

2

SMD, −0.10 (−0.37 to 0.18)

44

Young adult

5

SMD, 0.02 (−0.16 to 0.15)

26

Adult

6

SMD, −0.18 (−0.44 to 0.04)

80

Face-to-face

9

SMD, −0.11 (−0.28 to 0.03)

70

Other (web, computer, telephone)

5

SMD, −0.03 (−0.28 to 0.16)

44

Good

3

SMD, −0.02 (−0.41 to 0.22)

72

Fair

10

SMD, −0.12 (−0.27 to 0.03)

62

.57

.27

.03

.56

.63

.69

Abbreviations: MD, mean difference; RR, risk ratio; SMD, standardized mean difference.
a

Test of difference not conducted.

b

Standardized to drug use in the past 7 days.

Sensitivity and specificity for detecting any prenatal drug use
reported by pregnant or postpartum persons were generally lower
than the estimates for nonpregnant persons and ranged from 0.37
to 0.76 (95% CI range, 0.24 to 0.86) and 0.68 to 0.83 (95% CI range,
0.55 to 0.91), respectively (3 studies, n = 1456). All studies used hair
and urine analyses to validate drug use (Table 1; eTable 6 in the
Supplement). The 4P’s Plus, an indirect screening instrument, had
a sensitivity of 0.87 (95% CI, 0.71 to 0.95) and specificity of 0.76
(95% CI, 0.70 to 0.82) for detecting any prenatal alcohol or drug use
when compared with a diagnostic interview (n = 228) (eTable 6 in
the Supplement).
For adolescents, most studies focused on cannabis use. Sensitivity of frequency- and risk-based instruments for any cannabis use
or unhealthy cannabis use ranged from 0.68 to 0.98 (95% CI range,
0.64 to 0.99) and specificity ranged from 0.82 to 1.00 (95% CI range,
0.80 to 1.00) (Table 1; eTable 7 in the Supplement) (3 studies,
n = 2228). Sensitivity and specificity for identifying a cannabis use
disorder for frequency- and risk-based instruments ranged from 0.71

to 0.98 (95% CI range, 0.41 to 0.99) and 0.79 to 0.95 (95% CI range,
0.77 to 0.98), respectively (6 studies, n = 5735).

Harms of Screening
Key Question 3. What are the harms of primary care screening for
drug use in adolescents and adults, including pregnant women?
No eligible studies were identified.

Benefits of Interventions
Key Question 4. Do interventions to reduce drug use reduce drug
use or improve other risky behaviors? Do interventions to reduce
drug use reduce morbidity or mortality or improve other health,
social, or legal outcomes?
Psychosocial Interventions

Fifty-two trials (reported in 65 publications) evaluated a psychosocial intervention for unhealthy drug use or drug use disorders
(n = 15 659) (eTable 8 in the Supplement).54-118 Twenty-seven trials
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enrolled patients identified through screening and 25 trials
enrolled patients seeking substance use treatment or with known
substance use (“treatment-seeking”). The severity of baseline substance use varied considerably, with only 5 trials (all among
treatment-seeking persons)55,69-72 requiring patients to meet DSM
criteria for drug use disorder.
The primary substance used was cannabis in 29 trials, stimulants in 6 trials, opioids in 2 trials, and mixed or multiple drugs in 15
trials. Among the trials reporting mixed or multiple drug use, the proportion of patients reporting opioid use ranged from 5% to 26%. Five
trials evaluated interventions in adolescents, 8 in young adults (18-25
years), and 7 trials in mixed populations of adolescents or young
adults. Thirty-two trials evaluated adults or mixed populations of
adults and adolescents, including 3 trials of postpartum adults and
2 trials of pregnant adults.
Thirty-seven trials evaluated a brief psychosocial intervention
and 19 trials evaluated more intensive interventions (number of sessions ranged from 2 to 14, except 1 trial with 57 sessions); some of
these trials were multigroup (eTable 9 in the Supplement). The most
commonly used techniques in the psychosocial intervention trials
were motivational interventions and CBT. The mode of delivery was
in-person in 37 trials; by computer, internet, or telephone in 12 trials;
and by multiple modes of delivery in 3 trials. The control intervention consisted of a minimal intervention in 30 trials, waitlist in 11 trials,
and usual care in 11 trials. Minimal intervention controls typically consisted of brief education.
Eight trials were rated good quality and the remainder were
rated fair quality. Methodological limitations in the fair-quality trials
included high attrition, failure to blind or unclear blinding of outcome assessors, and unclear randomization methods. In these trials,
blinding of patients and clinicians was not feasible, given the nature of the interventions. Attrition at 3 to 4 months ranged from 2%
to 67% and at 6 to 12 months from 2% to 46%.
Results of the psychosocial trials are presented in Table 2 and
in eTable 10 in the Supplement. Psychosocial interventions were
associated with increased likelihood of abstinence from drug use vs
control conditions at 3 to 4 months (15 trials, n = 3636; risk ratio
[RR], 1.60 [95% CI, 1.24 to 2.13]; I2 = 61%; absolute risk difference
[ARD], 9% [95% CI, 5% to 15%]) (eFigure 1 in the Supplement) and
at 6 to 12 months (14 trials, n = 4031; RR, 1.25 [95% CI, 1.11 to 1.52];
I2 = 38%; ARD, 6% [95% CI, 2% to 10%]) (Table 2; eFigure 2 and
eTable 10 in the Supplement). At 3 to 4 months, psychosocial interventions were also associated with decreased number of days of
drug use during the last 7 days vs controls (19 trials, n = 5085;
mean difference [MD], –0.49 day [95% CI, –0.85 to –0.13];
I2 = 89%) (eFigure 3 in the Supplement) and drug use severity (17
trials, n = 4437; standardized MD, –0.18 [95% CI –0.32 to –0.05];
I2 = 73%) (eFigure 5 in the Supplement), but these associations
were smaller and not statistically significant at 6 to 12 months for
drug use days (15 trials, n = 5095; MD, –0.08 [95% CI, –0.30 to
0.11]; I2 = 45%) (eFigure 4 in the Supplement) or severity (13 trials,
n = 3798; standardized MD, –0.10 [95% CI, –0.24 to 0.02];
I2 = 65%) (eFigure 6 in the Supplement).
At 3 to 4 months, the associations with drug use days were statistically significantly greater among trials of treatment-seeking vs
screen-detected populations (10 trials, n = 1664; MD, –0.91 [95%
CI, –1.52 to –0.31] vs 9 trials, n = 3421; MD, –0.10 [95% CI, –0.31 to
0.12]; P = .02) and for intensive vs brief interventions (10 trials,
2318
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n = 2364; MD, –0.88 [95% CI, –1.50 to –0.28] vs 9 trials, n = 2721;
MD, –0.13 [95% CI, –0.36 to 0.12]; P = .03) (Table 2). Otherwise, statistically significant differences were not present in stratified analyses, although effects were generally stronger across outcomes in
trials of treatment-seeking vs screen-detected populations, cannabis use vs other types of drug use, intensive vs brief interventions,
and (for abstinence) in-person vs other modes of delivery.
Data on effects of psychosocial interventions on other health,
social, and legal outcomes were limited. These data, however, generally showed no differences between psychosocial interventions
vs control conditions in the likelihood of injection drug use or sexual
risk behaviors56-59,98,102,105,119; the risk of emergency department
visits or hospital admissions107,119; measures related to mental health,
quality of life, or function55,56,58,80,81,84,89,107,119; the likelihood of driving after cannabis use66,67,85; and risk of incarceration or involvement in criminal activity.56-58,88,102
Pharmacological Therapies
Opioid Agonist Therapy (Methadone and Buprenorphine) | Seven trials
(reported in 9 publications) (n = 1109) reported effects of opioid agonist therapy (buprenorphine or methadone) vs placebo or no medication (waitlist or usual care) for opioid use disorder (eTable 11 in the
Supplement).120-128 Two trials evaluated oral methadone, with dosing of up to 90 mg/d in one trial and averaging 78 mg/d in the other
trial (eTable 12 in the Supplement). The other 5 trials evaluated buprenorphine: sublingual administration in 3 trials (dose, 8-24 mg/d),
implant in 1 trial (4 implants, with a total dose of 320 mg), and both
sublingual and implant in 2 separate groups in the remaining trial.124
The duration of treatment ranged from 3 to 12 months (6 months
in 4 trials and 3, 4, or 12 months in 1 trial each). Oral methadone and
sublingual buprenorphine were administered daily under direct observation, although some trials allowed take-home doses for weekends and holidays. In 5 of the 7 trials, all patients received some drug
use counseling (individual, group, or both). The intensity of counseling ranged from “minimal” (not described) to “standard” counseling for 45 to 60 minutes on a weekly or twice-weekly basis. Two
trials of bridging therapy with methadone or buprenorphine did not
include a counseling intervention.
In all 7 trials of opioid agonist therapy, the main type of opioid
used was heroin; 2 trials reported prescription opioids as the main
opioid used by about one-third of patients. Four trials were conducted in the US, 2 trials in Europe, and 1 trial in Malaysia. In all
trials, patients were treatment-seeking. Patients were enrolled
from inpatient settings in 1 trial, from the community in 1 trial, and
from outpatient addiction treatment settings in 5 trials. In all but 1
trial, treatment was administered in outpatient addiction treatment settings.
Study participants were predominantly men (proportion of
women ranged from 25%-43%), and mean age ranged from 29 to
43 years. No study was conducted in adolescents, and no trial stratified outcomes by patient sex. In studies that reported the duration
of drug use, the mean ranged from 5 to 20 years. Three studies reported the mean number of days of heroin use during the last 30
days, ranging from 19 to 30 days.
Two studies were rated good quality and the remainder were
rated fair quality. Methodological shortcomings in the fair-quality
trials included unclear randomization or allocation concealment
methods and unclear or high attrition. Both methadone trials used
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Table 3. Summary of Pooled Findings: Pharmacological Interventions (Key Question 4)
Outcome,
Timing

Study characteristics

Group analyzed

No. of trials

Effect size, RR (95% CI)

I2, %

P value

Opioid agonists
Relapse
All time
points

All trials

All participants

4

0.75 (0.59 to 0.82)

75

Drug

Buprenorphine

3

0.59 (0.21 to 1.31)

84

Methadone

1

0.71 (0.61 to 0.84)

Type of counseling

Study quality

Buprenorphine
administration route

Standard counseling

3

0.59 (0.21 to 1.31)

No counseling

1

0.71 (0.61 to 0.84)

.78
84
.78

Good

2

0.75 (0.65 to 0.85)

0

Fair

2

0.46 (0.08 to 2.19)

93

Sublingual

2

0.46 (0.08 to 2.19)

93

Implant

1

0.77 (0.68 to 0.88)

.54

.70

Retention in
treatment
All time
points

All trials

All participants

7

2.58 (1.78 to 4.59)

71

Drug

Buprenorphine

5

2.52 (1.89 to 4.74)

51

Methadone

2

2.22 (0.63 to 7.56)

92

Standard counseling

5

2.09 (1.54 to 3.33)

56

Minimal or no counseling

3

2.78 (0.93 to 13.74)

86

Type of counseling

Study quality

Good quality

2

3.15 (1.90 to 4.81)

42

Fair quality

5

2.34 (1.41 to 9.20)

73

Buprenorphine
administration route

Sublingual

4

2.95 (1.97 to 12.06)

57

Implant

2

2.27 (1.58 to 3.31)

0

All trials

All participants

12

0.72 (0.62 to 0.85)

78

Route of administration

Oral

11

0.76 (0.65 to 0.88)

70

Injection or implant

2

0.41 (0.06 to 2.40)

98

Receiving treatment

10

0.71 (0.59 to 0.84)

82

After intervention

2

0.93 (0.54 to 1.50)

0

.54

.79

.72

.46

Naltrexone
Relapse
All time
points

Timing of outcome
assessment
Study quality

Good quality

3

0.67 (0.48 to 0.94)

84

Fair quality

9

0.76 (0.61 to 0.91)

78

Naltrexone dose (oral
administration)

≤50 mg/d

7

0.69 (0.58 to 0.81)

47

>50 mg/d

4

0.97 (0.81 to 1.11)

0

All trials

All participants

9

1.71 (1.13 to 2.49)

67

Route of administration

Oral

8

1.59 (1.00 to 2.38)

61

Injection or implant

2

2.48 (0.58 to 11.75)

94

Receiving treatment

8

1.89 (1.36 to 2.65)

59

After intervention

1

0.39 (0.14 to 1.14)

.13

.36

.52

.70

Retention in
treatment
All time
points

Timing of outcome
assessment
Study quality

Naltrexone dose (oral
administration)

.37

.05

Good

3

2.10 (1.21 to 4.13)

78

Fair

6

1.43 (0.78 to 2.47)

67

≤50 mg/d

6

1.84 (1.22 to 2.71)

49

>50 mg/d

2

0.82 (0.14 to 4.48)

73

.33

.18

Abbreviation: RR, risk ratio.

an unblinded design—one trial compared methadone vs usual care
and the other trial compared methadone vs wait-list control.
Results of trials of methadone and buprenorphine are summarized in Table 3 and eTable 13 in the Supplement. After 4 to 12 months
of treatment, opioid agonist therapy was associated with decreased risk of relapse vs controls (4 trials, n = 567; RR, 0.75 [95%
CI, 0.59 to 0.82]; I2 = 75%; ARD, –35% [95% CI, –67% to –13%])

(eFigure 7 in the Supplement) and an increased likelihood of treatment retention (7 trials, n = 1099; RR, 2.58 [95% CI, 1.78 to 4.59];
I2 = 71%; ARD, 39% [95% CI, 23% to 54%]) (eFigure 8 in the Supplement). There was no significant difference between type of drug
(methadone or buprenorphine), buprenorphine administration
method (sublingual or by implant), counseling intensity, or trial quality and effects on relapse or retention.
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Evidence on health outcomes associated with opioid agonist
therapy vs placebo or no opioid agonist was very limited. Only 3 trials
reported on a measure of global function or well-being with no clear
effect. Mortality was reported in 2 trials of buprenorphine with a total
of 4 deaths, all in patients randomized to placebo. No trial reported
on the social or legal outcomes of opioid agonist therapy.
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was rare, with a total of 3 deaths (2 in naltrexone groups and 1 in placebo groups) in 5 trials.

Harms of Interventions
Key Question 5. What are the harms of interventions to reduce
drug use (including illicit drug use and nonmedical pharmaceutical drug use)?

Naltrexone | Thirteen trials (in 14 publications) (n = 1718) evaluated

naltrexone vs placebo or no naltrexone for opioid use disorder
(generally based on meeting DSM-II-R, DSM-III, or DSM-IV criteria)
(eTable 14 in the Supplement).125,129-141 All patients in the trials
received drug use counseling, usually described as individual or
group counseling ranging from 3 times per week to biweekly.
Details on counseling methods, however, were limited. Eleven trials
assessed oral naltrexone, 1 trial injectable naltrexone (300 mg
every 4 weeks), and 1 trial had 2 active groups of a naltrexone
implant (1000 mg twice a month) and oral naltrexone (eTable 15 in
the Supplement). The oral naltrexone dose was 50 mg daily in 7
trials, up to 150 mg daily in 2 trials, and 100 or 150 mg 2 or 3 times
weekly in 3 trials. Treatment duration was 6 months in 10 trials and
2, 3, or 9 months in the other 3 trials. Outcomes were assessed at
the end of treatment in all trials except for 2 trials that evaluated
outcomes 6 or 10 months after treatment completion. Five trials
were conducted in Russia, 2 in Israel, 2 in the US, 2 in Europe, 1 in
Malaysia, and 1 in China. Patients were recruited from inpatient settings, drug treatment settings, or from the criminal justice system
(eg, parolees). No study recruited patients from primary care settings. In all cases, naltrexone treatment was administered in outpatient settings.
Where reported, heroin was the primary opioid of use in all or
most patients in naltrexone treatment trials. Studies enrolled predominantly men (proportion of women ranged from 0% to 31%),
and no trial reported outcomes stratified by patient sex. The mean
age ranged from 21 to 29 years, with no trials of adolescents. All trials
required patients to be withdrawn from opioids prior to initiation of
naltrexone. Four trials described inpatient or residential withdrawal from opioids; details were otherwise not well reported.
Three studies were rated good quality and the remainder
were rated fair quality. Methodological shortcomings in the fairquality trials included unclear randomization or allocation concealment methods and unclear or high attrition. All trials were
blinded.
Results of the naltrexone trials are presented in Table 3 and in
eTable 16 in the Supplement. In pooled analyses, naltrexone was
associated with decreased risk of relapse vs placebo or no naltrexone (12 trials, n = 1599; RR, 0.73 [95% CI, 0.62 to 0.85]; ARD,
–18% [95% CI, –26% to –10%]) (eFigure 9 in the Supplement), as
well as an increased likelihood of treatment retention (9 trials,
n = 1404; RR, 1.71 [95% CI, 1.13 to 2.49]; I2 = 67%; ARD, 15% [95%
CI, 5% to 22%]) (eFigure 10 in the Supplement). There was no significant difference in the likelihood of relapse or treatment retention based on route of naloxone administration. Results were
similar when analyses were restricted to trials of oral naltrexone
at a dose of 50 mg/d and to good-quality trials.
Evidence on the effects of naltrexone vs placebo or no naltrexone on health outcomes (eg, global function, quality of life, depression, and anxiety) was limited, with no consistent evidence of a benefit of naltrexone compared with placebo or no naltrexone. Mortality
2320
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Four trials of psychosocial interventions (n = 1196) reported no adverse events in either intervention or control groups (eTable 10 in
the Supplement).94,98,99,142 Harms were otherwise not reported,
with no serious adverse events noted.
Pharmacological Therapies
Opioid Agonist Therapy (Buprenorphine or Methadone) | Four trials
of buprenorphine vs placebo reported harms122-125; no trials of
methadone reported harms (eTable 13 in the Supplement). There
was no significant difference between buprenorphine vs placebo in
risk of serious adverse events, which were uncommon (2 trials,
n = 450; RR, 0.32 [95% CI, 0.09 to 1.12]; I2 = 0%)123,124; 1 trial
reported no hospitalizations due to serious medication-related
adverse events.125 One trial (n = 83) found no significant difference
between buprenorphine vs placebo in risk of withdrawal due to
adverse events (RR, 0.89 [95% CI, 0.06 to 13.7]),125 and 1 trial
(n = 287) found no difference in risk of any adverse event (RR, 1.14
[95% CI, 0.90 to 1.43]).124 Buprenorphine was also not associated
with increased risk of diaphoresis (3 trials, n = 476; RR, 1.15 [95%
CI, 0.55 to 2.73]; I2 = 44%)122,124,125 or nausea (3 trials, n = 393; RR,
1.13 [95% CI, 0.41 to 6.07]; I2 = 30%).122,124 Buprenorphine was
associated with increased risk of constipation vs placebo, based on
2 trials (n = 246; RR, 2.36 [95% CI, 1.16 to 4.92]; I2 = 0%; ARD, 12%
[95% CI, –5% to 41%]).123,125
Naltrexone | Eleven trials of naltrexone vs placebo or no medication reported harms (n = 1645) (eTable 16 in the Supplement).125,129-136,139,140 For withdrawal from study due to adverse
events, 3 trials found no difference between naltrexone vs placebo or no medication, but the estimate was imprecise (n = 836;
RR, 1.54 [95% CI, 0.35 to 8.31]; I2 = 0%).133-135 Three other trials
(n = 181) reported no study withdrawals due to adverse
events.125,130,139 Three studies (n = 638) found no differences in
serious adverse events, but the estimate was imprecise (RR, 1.24
[95% CI, 0.11 to 10.21]; I2 = 59%).125,134,135 Three trials (n = 163)
found no differences between naltrexone and control groups in
risk of gastrointestinal adverse events (constipation, diarrhea,
and nausea or vomiting).125,130,140

Benefits of Naloxone Preemptive Prescribing
Key Question 6. Does naloxone reduce morbidity or mortality, or improve other health outcomes, in persons with opioid use disorder
or misuse?
No eligible studies were identified.

Harms of Naloxone Preemptive Prescribing
Key Question 7. What are the harms of naloxone in persons with opioid use disorder or misuse?
No eligible studies were identified.
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Study design

No studies

28 Observational
studies
(n = 65 720)b
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No studies

Psychosocial
interventions

52 trials
(n = 15 659)
Screen-detected
populations: 27
trials (n = 10 227)
Treatment-seeking
populations: 25
trials (n = 5432)

KQ4a and KQ4b: Efficacy of interventions

NA

KQ3: Harms of screening

NA (test accuracy
only)

KQ2: Screening accuracy

NA

KQ1: Benefits of screening

Intervention

Table 4. Summary of Evidence

NA

Consistency and precision

Drug use abstinence:
3 to 4 mo: 15 trials; RR, 1.60 (95% CI, 1.24 to 2.13);
I2 = 61%; ARD, 9% (95% CI, 5% to 15%)
6 to 12 mo: 14 trials; RR, 1.25 (95% CI, 1.11 to 1.52);
I2 = 38%; ARD, 10% (95% CI, 3% to 16%)
Drug use days (in last 7 d):
3 to 4 mo: 19 trials; MD, −0.49 d (95% CI, −0.85 to
−0.13); I2 = 89%
6 to 12 mo: 15 trials; MD, −0.08 d (95% CI, −0.30 to
0.11); I2 = 45%
Drug use severity:
3 to 4 mo: 17 trials; SMD, −0.18 (95% CI, −0.32 to
−0.05); I2 = 73%
6 to 12 mo: 13 trials; SMD, −0.10 (95% CI, −0.24 to
0.02); I2 = 65%
Mortality: reported in 4 trials with few events
Other health, social, and legal outcomes: few trials,
with inconsistent effects

NA

Substantial clinical
heterogeneity and
inconsistency
Effects present in trials of
treatment-seeking but not
screen-detected populations
Effects also generally stronger
in trials that evaluated
cannabis use than other type
of drug use, trial of adult than
trial of adolescents or young
adults, and trial of more
intensive than brief
interventions
No stratified analysis explained
inconsistency

NA

Reasonably consistent
Thirty different screening tools evaluated, including
and imprecise
brief frequency-based tools, risk assessment tools,
and indirect screeners
Among adolescents, sensitivity of frequency-based
and risk assessment tools for detecting any cannabis
use or unhealthy cannabis use ranged from 0.68 to
0.98 (95% CI, 0.64 to 0.99) and specificity ranged
from 0.82 to 1.00 (95% CI, 0.80 to 1.00)
Among adults, sensitivity of frequency-based and risk
assessment tools for detecting unhealthy use of “any
drug” ranged from 0.71 to 0.94 (95% CI, 0.62 to
0.97) and specificity ranged from 0.87 to 0.97 (95%
CI, 0.83 to 0.98)
Instruments were less accurate in detecting unhealthy
use of prescription opioids or sedatives then other
specific drugs, especially cannabis; sensitivity and
specificity of frequency-based and risk assessment
tools for detecting any prenatal drug use (not
including alcohol) was lower than the estimates found
for nonpregnant adults and ranged from 0.37 to 0.76
(95% CI, 0.24 to 0.86) and from 0.68 to 0.83 (95%
CI, 0.55 to 0.91)

NA

Summary of findingsa
Insufficient

Strength of
evidence

Overall risk of bias moderate;
attrition was high
Trials of psychosocial
interventions could not be
effectively blinded
Methods for measuring drug
use outcomes varied
Reporting bias not detected

Insufficient

Moderate

NA

Low
Each instrument was not
evaluated in more than 1 or 2
studies
No studies restricted inclusion
to young adults specifically
(the age group with the highest
prevalence of use)
Low prevalence of some drugs
makes it difficult to determine
if the screening tools are
accurate for those substance
Few studies included biologic
confirmation of drug use
Few studies among pregnant
persons using brief screeners

NA

Other limitations

© 2020 American Medical Association. All rights reserved.

(continued)

Studies varied in terms of whether patients
were screen-detected or treatment-seeking,
recruitment setting, and severity and type of
drug use
Most trials evaluated psychosocial
interventions that used cognitive behavioral
therapy or motivational interventions, but
treatment intensity varied
Brief interventions are usually designed to be
feasible for delivery in primary care settings

NA

Most studies conducted in US-based primary
care population, although included studies
represented samples with generally higher
prevalence of drug use and drug use
disorders than US national estimates
Higher representation of nonwhite and low
SES participants

NA

Applicability
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Withdrawal due to adverse events: 3 trials; RR, 1.54
(95% CI, 0.35 to 8.31); I2 = 0%

11 trials
(n = 1645)

4 trials (n = 639)
on buprenorphine;
no studies on
methadone

Naltrexone for
opioid use
disorder

Opioid agonist
therapy
(buprenorphine or
methadone) for
opioid use
disorder
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Withdrawal due to adverse events: 1 trial; RR, 0.89
(95% CI, 0.06 to 13.7)
No hospitalizations due to serious medication-related
adverse events: 1 trial
Constipation: 2 trials; RR, 2.36 (95% CI, 1.17 to
4.92); I2 = 0%; ARD, 12% (95% CI, −5% to 41%)
Diaphoresis: 3 trials; RR, 1.15 (95% CI, 0.55 to 2.73);
I2 = 44%
Nausea: 2 trials; RR, 1.13 (95% CI, 0.41 to 6.07);
I2 = 30%

Serious adverse events: 2 trials; RR, 0.33 (95% CI,
0.09 to 1.12); I2 = 0%

Constipation: 2 trials; RR, 0.97 (95% CI, 0.37 to
2.39); I2 = 0%
Diarrhea: 2 trials; RR, 1.94 (95% CI, 0.70 to 6.53);
I2 = 0%

Serious adverse events: 3 trials; RR, 1.24 (95% CI,
0.11 to 10.21); I2 = 59%

No harms reported in either intervention of control
groups
No serious adverse events noted

4 trials (n = 1198)

Retention in treatment: 7 trials; RR, 2.58 (95% CI,
1.78 to 4.59); I2 = 71%; ARD, 39% (95% CI, 23% to
54%)
Results very similar when stratified by buprenorphine
or methadone
Mortality: reported in 2 trials, with very few events
Other health, legal, and social outcomes: few trials,
with inconsistent effects

Psychosocial
interventions

KQ5: Harms of interventions

Some inconsistency
and imprecision

Findings consistent
but imprecise

Findings consistent
but imprecise

For drug use relapse and
retention in treatment,
inconsistency in magnitude
but not direction of effect
Estimates reasonably precise
Results consistent in stratified
and sensitivity analyses

Drug use relapse: 4 trials; RR, 0.75 (95% CI, 0.59 to
0.82); I2 = 75%; ARD, −35% (95% CI, −67% to −3%)

7 trials (n = 1109)
Buprenorphine: 5
trials (n = 679)
Methadone: 2 trials
(n = 430)
All trials conducted
in
treatment-seeking
individuals

Opioid agonist
therapy
(buprenorphine or
methadone) for
opioid use
disorder

Retention in treatment: 9 trials; RR, 1.71 (95% CI,
1.13 to 2.49); I2 = 67%; ARD, 15% (95% CI, 5% to
22%)
Mortality: Reported in 5 trials, with very few events
Other health, legal, and social outcomes: few trials,
with inconsistent effects

For drug use relapse and
retention in treatment,
inconsistency in magnitude
but not direction of effect
Estimates reasonably precise
Results consistent in stratified
and sensitivity analyses

Drug use relapse: 11 trials; RR, 0.73 (95% CI, 0.62 to
0.85); I2 = 78%; ARD, −18% (95% CI, −26% to −10%)

13 trials
(n = 1718)

Naltrexone for
opioid use
disorder

Consistency and precision

Summary of findingsa

Study design

Intervention

Table 4. Summary of Evidence (continued)

Overall risk of bias moderate
Harms reporting was
inconsistent, and harms not
reported by all trials

Overall risk of bias moderate
Harms reporting was
inconsistent, and harms not
reported by all trials

Overall risk of bias moderate
Harms only reported in a few
trials; however, serious harms
not expected with this type of
intervention

Overall risk of bias moderate;
attrition was high
Two trials used an open-label
design
Methods for defining drug use
relapse used urine drug test
findings
Reporting bias not detected

Overall risk of bias moderate;
attrition was high
Methods for defining drug use
relapse and retention in
treatment varied
Reporting bias not detected

Other limitations

All trials enrolled treatment-seeking persons
with opioid use disorder, primarily due to
heroin use
Opioid agonist therapy usually administered
in conjunction with drug use counseling
Opioid agonist therapy usually administered
in addiction treatment setting
No trial evaluated newly FDA-–approved,
injectable buprenorphine

All trials enrolled treatment-seeking persons
with opioid use disorder due to heroin use
Naltrexone administered in conjunction with
drug use counseling
Most trials evaluated oral naltrexone, some
trials recruited patients from the criminal
justice system, and around one-half of
naltrexone trials were conducted in countries
in which opioid agonist therapy is not
available

Applicability

(continued)

Low-moderate See entry for efficacy of opioid agonist
therapy

Low-moderate See entry for efficacy of naltrexone

Low-moderate See entry for efficacy of psychosocial
interventions

Moderate

Moderate

Strength of
evidence

Clinical Review & Education US Preventive Services Task Force
USPSTF Report: Screening for Unhealthy Drug Use

jama.com

N includes 1 US-based community sample (n = 42 923) that only evaluated a single-item alcohol question for
predicting problematic drug use. Without this study, total n = 22 797.

NA
Insufficient
NA

Comparisons are against placebo or no medication for pharmacological interventions and against waitlist, a
minimal intervention, or usual care for psychosocial interventions.
a

Abbreviations: ARD, absolute risk difference; FDA, US Food and Drug Administration; MD, mean difference;
NA, not applicable; RR, risk ratio; SES, socioeconomic status; SMD, standardized mean difference.

US Preventive Services Task Force Clinical Review & Education

Discussion

b

NA
NA
No studies
NA

NA
NA
No studies

KQ7: Harms of naloxone preemptive prescribing

NA

KQ6: Efficacy of naloxone preemptive prescribing

Summary of findingsa
Study design
Intervention

Table 4. Summary of Evidence (continued)

Consistency and precision

NA

Other limitations

Strength of
evidence

Insufficient

NA

Applicability

USPSTF Report: Screening for Unhealthy Drug Use

This review updates the 2008 USPSTF review on screening for
drug use in adolescents and adults. 5 A summary of findings,
including an assessment of the strength of evidence for each KQ,
is presented in Table 4. Consistent with the 2008 review, no studies were identified on the benefits and harms of screening (vs no
screening) for drug use in primary care. However, evidence indicates that several screening instruments, including single-item
drug frequency questions 18,20,45,48 ; the Substance Use Brief
Screen 18 ; the Tobacco, Alcohol, Prescription Medication, and
Other Substance Use tool25,49; and the Drug Abuse Screening Test
(10 items),20 can detect unhealthy drug use with reasonable accuracy. Both frequency-based and risk assessment screening instruments generally have sensitivity greater than or equal to 0.80 and
specificity greater than or equal to 0.85 for identifying unhealthy
drug use and drug use disorders among adults when validated
against a structured diagnostic interview. Based on the range in
test accuracy estimates and a prevalence of drug use among
adults of 11%,3 the positive predictive value of screening instruments is approximately 40%. In patients who screen positive, further assessment to define patients’ risk level may help determine
the appropriateness for treatment, such as the procedure recommended by the National Institute on Drug Abuse.143
Compared with the 2008 review, substantially more evidence
is available to support the effectiveness of psychosocial interventions and FDA-approved medications to improve drug use outcomes among persons with unhealthy drug use or a diagnosed drug
use disorder. When trials in screen-detected and treatmentseeking populations were combined in the meta-analyses, psychosocial interventions were associated with an increased likelihood of
drug use abstinence, decreased number of drug use days, and decreased drug use severity at 3 to 4 months. Beneficial effects at 6
to 12 months were only observed for drug use abstinence. Most trials
of psychosocial interventions recruited patients with cannabis use
or mixed drug use and used CBT or motivational interventions ranging in intensity from 1 or 2 sessions to ongoing treatment for months.
Based on overall pooled estimates, psychosocial interventions were
associated with a number needed to treat of 17 for 1 additional case
of drug use abstinence at 6 to 12 months. Effects were generally
greater in treatment-seeking populations than in screen-detected
populations, stronger for cannabis use than other drug use outcomes, stronger for shorter-term (3- to 4-month) than longer-term
(6- to 12-month) outcomes, and stronger for more intensive interventions vs brief interventions. Few trials evaluated psychosocial interventions among adolescents or pregnant persons.
Both opioid agonist therapy (methadone and buprenorphine)
and naltrexone were associated with a decreased risk of relapse and
increased likelihood of treatment retention among individuals with
an opioid use disorder after 4 to 12 months of treatment, compared with no treatment. Trials of pharmacologic treatment were
primarily conducted in persons using heroin, and medications were
typically administered in conjunction with drug use counseling, in
accordance with recommended practice.14,144 Based on pooled estimates, the number needed to treat to avoid 1 additional case of relapse was 3 for opioid agonists and 6 for naltrexone. There was no
evidence that the effectiveness of pharmacologic treatment varied
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according to type of medication, administration method, intensity
of co-occurring counseling, or trial quality.
Evidence on the effects of psychosocial and medications for opioid use disorder on health outcomes (eg, such as global function,
quality of life, depression, and anxiety) was very limited and showed
no consistent evidence of a benefit of treatment compared with no
treatment. While assessment and reporting of harms in trials of pharmacotherapies was suboptimal, it indicated no increase in risk of serious adverse events or study withdrawal due to adverse events vs
placebo or pharmacotherapy. Trials of psychosocial interventions
generally did not report harms, although serious harms are not anticipated with this type of intervention.
As described in the full report,8 evidence on the benefits and
harms of preemptive prescribing of naloxone in primary care settings for reducing overdose risk in persons with opioid use disorder
or misuse is not available. To date, the effectiveness of naloxone
has mainly been demonstrated in the context of evaluations
of community opioid overdose prevention and naloxone distribution programs.145,146

Limitations
This study had several limitations. First, for screening accuracy, despite inclusion criteria designed to result in the selection of studies
highly applicable to US primary care, many screening studies were
conducted in populations with high prevalence of drug use or high
numbers of known drug users, and some of the larger studies were
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conducted among non–clinic-based samples. As such, the instrument accuracy reported in the included studies may not reflect the
accuracy for all US primary care settings.
Second, trials of psychosocial interventions were characterized by marked variability in patient populations, interventions, outcomes, recruitment and treatment settings, and other factors, likely
contributing to the substantial statistical heterogeneity observed in
pooled analyses. Furthermore, evidence was lacking on the effectiveness of psychosocial treatments among adolescents and pregnant people as well as for treatment of stimulant use. Most trials of
medication therapy were among adults with opioid use disorder due
to heroin use and not prescription opioid misuse.
Third, trials primarily focused on intermediate outcomes, such
as drug use or retention in treatment, and there was little direct evidence on the effects of interventions on mortality or other clinical,
social, and legal outcomes.

Conclusions
Several screening instruments with acceptable sensitivity and specificity are available to screen for drug use, although there is no evidence on the benefits or harms of screening. Pharmacotherapy and
psychosocial interventions are effective at improving drug use outcomes, but evidence of effectiveness remains primarily derived from
trials conducted in treatment-seeking populations.
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